Wesley H. Kaupinen

Wesley H. Kaupinen

President and Chief Executive OfficeratPalvella Therapeutics· In proxies 2023–2025

Pay in FY2025-37% from the year before · Palvella Therapeutics stock +772.3% the same year

Wesley H. Kaupinen was paid $3.4M in FY2025 (Dec), down 37%. Palvella Therapeutics stock rose 772.3% that year.

Pay$100 in the stock at the end of FY22 → $126
Pay is from the Summary Compensation Table of each Palvella Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Palvella TherapeuticsPublic company · 3 yr
    • President and Chief Executive Officer2023 – Present · 3 yrStock in role +109%
  2. Biocoat Holdings, LLCPublic company
    • Director? – PresentNo stock prices for these years
  3. Intact Vascular, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. TELA Bio, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?